Chunyan Ma Clinical Oncology Society of Australia Annual Scientific Meeting 2023

Abstracts this author is presenting:

• Lenvatinib vs sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC) and nonviral etiology: REFLECT post-hoc analysis — Lunch, Poster Viewing, Exhibition & COSA Group Meetings
• A phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, plus lenvatinib in patients with advanced hepatocellular carcinoma (HCC) — Lunch, Poster Viewing, Exhibition & COSA Group Meetings